Fig. 2
Clinical impact of RBM3 immunostaining. Relationship of RBM3 immunostaining with overall survival in EACs (P = 0.212; a) and ESCCs (P = 0.5992; b)
Fig. 2 | BMC Cancer
Clinical impact of RBM3 immunostaining. Relationship of RBM3 immunostaining with overall survival in EACs (P = 0.212; a) and ESCCs (P = 0.5992; b)